JPH07504888A - CDw52−多発性硬化症の治療のための特異抗体 - Google Patents
CDw52−多発性硬化症の治療のための特異抗体Info
- Publication number
- JPH07504888A JPH07504888A JP5509973A JP50997393A JPH07504888A JP H07504888 A JPH07504888 A JP H07504888A JP 5509973 A JP5509973 A JP 5509973A JP 50997393 A JP50997393 A JP 50997393A JP H07504888 A JPH07504888 A JP H07504888A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- treatment
- multiple sclerosis
- campath
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (15)
- 1.CDw52抗原を認識する抗体の、多発性硬化症の治療のための医薬の製造 への使用。
- 2.抗体がマウスもしくはラット抗体由来のCDRを含むヒト化抗体であり、該 CDRが1種以上のヒト抗体由来のフレームワーク領域および定常ドメインと結 合している請求の範囲第1項記載の使用。
- 3.抗体がCAMPATH−1Hである請求の範囲第2項記載の方法。
- 4.治療には、1日当り1ないし10mgの投与量で1ないし30日の期間、患 者に毎日投与することが含まれる請求の範囲第1項ないし第3項のいずれか1項 に記載の使用。
- 5.治療にはステロイドの投与が含まれる請求の範囲第4項記載の使用。
- 6.CDw52抗原を認識する抗体を活性成分として含有する、多発性硬化症を 治療するための治療薬。
- 7.抗体がマウスもしくはラット抗体由来のCDRを含むヒト化抗体であり、該 CDRが1種以上のヒト抗体由来のフレームワーク領域および定常ドメインと結 合している請求の範囲第6項記載の治療薬。
- 8.抗体がCAMPATH−1Hである請求の範囲第7項記載の治療薬。
- 9.抗体の1日投与量が、1ないし30日の期間、1日当り1ないし10mgで ある請求の範囲第6項ないし第8項のいずれか1項に記載の治療薬。
- 10.治療にはステロイドの投与が含まれる請求の範囲第6項ないし第9項のい ずれか1項に記載の治療薬。
- 11.多発性硬化症に罹患したヒト患者の治療方法であってCOw52抗原を認 識する抗体の有効量を該患者に投与することを具備する方法。
- 12.抗体がマウスもしくはラット抗体由来のCORを含むヒト化抗体であり、 該CDRが1種以上のヒト抗体由来のフレームワーク領域および定常ドメインと 結合している請求の範囲第11項記載の方法。
- 13.抗体がCAMPATH−1Hである請求の範囲第12項記載の方法。
- 14.1日当り1ないし10mgで1ないし30日の期間、抗体を毎日投与する ことを具備する請求の範囲第11項ないし第13項のいずれか1項記載の方法。
- 15.有効量のステロイドを投与することを包含する請求の範囲第11項ないし 第14項のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9125768.3 | 1991-12-04 | ||
GB919125768A GB9125768D0 (en) | 1991-12-04 | 1991-12-04 | Therapeutic method |
PCT/GB1992/002252 WO1993010817A1 (en) | 1991-12-04 | 1992-12-04 | CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07504888A true JPH07504888A (ja) | 1995-06-01 |
JP3383303B2 JP3383303B2 (ja) | 2003-03-04 |
Family
ID=10705671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50997393A Expired - Lifetime JP3383303B2 (ja) | 1991-12-04 | 1992-12-04 | CDw52−多発性硬化症の治療のための特異抗体 |
Country Status (18)
Country | Link |
---|---|
US (2) | US6120766A (ja) |
EP (1) | EP0616537B1 (ja) |
JP (1) | JP3383303B2 (ja) |
KR (1) | KR100271333B1 (ja) |
AT (1) | ATE177011T1 (ja) |
AU (1) | AU3089692A (ja) |
CA (1) | CA2124964C (ja) |
DE (1) | DE69228556T2 (ja) |
DK (1) | DK0616537T3 (ja) |
ES (1) | ES2128363T3 (ja) |
GB (1) | GB9125768D0 (ja) |
GR (1) | GR3029683T3 (ja) |
HK (1) | HK1011618A1 (ja) |
IL (1) | IL103981A (ja) |
MX (1) | MX9207032A (ja) |
MY (1) | MY111961A (ja) |
WO (1) | WO1993010817A1 (ja) |
ZA (1) | ZA929446B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503631A (ja) * | 2006-09-13 | 2010-02-04 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US20060057107A1 (en) * | 2001-12-21 | 2006-03-16 | Shaked Ze Ev | Combination treatment for multiple sclerosis |
EP2034009B1 (en) | 2002-02-08 | 2014-01-15 | Life Technologies Corporation | Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation |
CA2490401A1 (en) | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
JP2006524991A (ja) * | 2003-05-08 | 2006-11-09 | エクサイト セラピーズ インコーポレーティッド | 抗原特異的t細胞の作製および単離の方法 |
CA2539716A1 (en) * | 2003-09-22 | 2005-04-07 | Xcyte Therapies, Inc. | Compositions and methods to accelerate hematologic recovery |
CN1898267B (zh) | 2003-11-01 | 2012-05-23 | 默克专利股份有限公司 | 修饰的抗cd52抗体 |
WO2007120834A2 (en) | 2006-04-13 | 2007-10-25 | Peptimmune, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
EP2538217A1 (en) | 2007-02-16 | 2012-12-26 | Genzyme Corporation | Method of identifying risk for thyroid disorder |
EP2160403B1 (en) * | 2007-05-11 | 2018-08-08 | Genzyme Corporation | Methods of producing a secreted protein |
KR101537840B1 (ko) * | 2009-05-13 | 2015-07-22 | 젠자임 코포레이션 | 항-인간 cd52 면역글루불린 |
AU2010248935B2 (en) | 2009-05-13 | 2016-12-15 | Genzyme Corporation | Methods and compositions for treating lupus |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
EP2736540B1 (en) | 2011-07-29 | 2019-03-13 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
ES2861435T3 (es) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
US9714278B2 (en) | 2012-02-22 | 2017-07-25 | The Trustees Of The University Of Pennsylvania | Use of ICOS-based CARs to enhance antitumor activity and CAR persistence |
CN104136458A (zh) | 2012-02-22 | 2014-11-05 | 宾夕法尼亚大学董事会 | 在第二代嵌合抗原受体中cd2信号传导结构域的使用 |
WO2014011984A1 (en) | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Toxicity management for anti-tumor activity of cars |
JP6482461B2 (ja) | 2012-07-13 | 2019-03-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 投与に関する形質導入t細胞の適合性の評価方法 |
KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강 |
US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
CN105518018B (zh) * | 2013-03-15 | 2020-04-03 | 细胞基因公司 | 修饰的t淋巴细胞 |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015112626A1 (en) | 2014-01-21 | 2015-07-30 | June Carl H | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
HUE054588T2 (hu) | 2014-04-07 | 2021-09-28 | Novartis Ag | Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával |
CA2984484C (en) | 2014-05-02 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CA2955154C (en) | 2014-07-21 | 2023-10-31 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
AU2015339744B2 (en) | 2014-10-31 | 2021-03-25 | The Trustees Of The University Of Pennsylvania | Altering gene expression in CART cells and uses thereof |
CN107106609A (zh) | 2014-10-31 | 2017-08-29 | 宾夕法尼亚大学董事会 | 刺激和扩展t细胞的组合物和方法 |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
CA2975147A1 (en) | 2015-01-31 | 2016-08-04 | Yangbing Zhao | Compositions and methods for t cell delivery of therapeutic molecules |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3259284B1 (en) | 2015-02-16 | 2020-04-01 | The Trustees of the University of Pennsylvania | A fully-human t cell receptor specific for the 369-377 epitope derived from the her2/neu (erbb2) receptor protein |
SG11201706947TA (en) | 2015-03-02 | 2017-09-28 | Innovative Cellular Therapeutics Co Ltd | Reducing immune tolerance induced by pd-l1 |
ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
CA2982996A1 (en) | 2015-04-17 | 2016-10-20 | David Maxwell Barrett | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
IL274151B (en) | 2015-05-21 | 2022-07-01 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
EP3340998B1 (en) | 2015-08-28 | 2023-01-11 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
EP3340995A4 (en) | 2015-08-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | METHODS AND COMPOSITIONS FOR CELLS EXPRESSING A CHIMERIC INTRACELLULAR SIGNALING MOLECULE |
CN108780084B (zh) | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
EP3359650A4 (en) | 2015-10-08 | 2019-03-20 | Innovative Cellular Therapeutics Co., Ltd. | ACTIVATION AND EXPANSION OF T CELLS |
WO2017091786A1 (en) | 2015-11-23 | 2017-06-01 | Novartis Ag | Optimized lentiviral transfer vectors and uses thereof |
JP7082055B2 (ja) | 2015-12-22 | 2022-06-07 | ノバルティス アーゲー | 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体(car)およびpd-l1阻害剤に対する抗体 |
US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
CN109219445B (zh) | 2016-04-01 | 2022-08-26 | 上海煦顼技术有限公司 | 嵌合抗原受体修饰细胞治疗癌症的应用 |
RU2018140056A (ru) | 2016-04-15 | 2020-05-15 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス,インク. | 単一ドメイン血清アルブミン結合タンパク質 |
AU2017299854A1 (en) | 2016-07-18 | 2019-01-31 | Helix Biopharma Corp. | CAR immune cells directed to carcinoembryonic antigen related cell adhesion molecule 6 to treat cancer |
JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法 |
CN117866991A (zh) | 2016-10-07 | 2024-04-12 | 诺华股份有限公司 | 用于治疗癌症的嵌合抗原受体 |
JP7217970B2 (ja) | 2016-10-07 | 2023-02-06 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を用いてt細胞受容体をリプログラミングするための組成物及び方法 |
EP3529359B1 (en) | 2016-10-18 | 2023-12-13 | Regents of the University of Minnesota | Tumor infiltrating lymphocytes for use in therapy |
WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
KR20190087539A (ko) | 2016-11-23 | 2019-07-24 | 하푼 테라퓨틱스, 인크. | Psma 표적화 삼중특이성 단백질 및 사용 방법 |
EA201991168A1 (ru) | 2016-11-23 | 2019-12-30 | Харпун Терапьютикс, Инк. | Белок, связывающий простатический специфический мембранный антиген |
WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
CA3047999A1 (en) | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
EP3609536B1 (en) | 2017-01-05 | 2022-03-09 | Innovative Cellular Therapeutics Holdings, Ltd. | Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
CN115028727A (zh) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | 靶向msln的三特异性蛋白质及使用方法 |
BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
US20210079057A1 (en) | 2017-06-13 | 2021-03-18 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
AU2018346955A1 (en) | 2017-10-13 | 2020-04-30 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
JP2021502979A (ja) | 2017-11-15 | 2021-02-04 | ノバルティス アーゲー | Bcmaターゲティングキメラ抗原受容体、cd19ターゲティングキメラ抗原受容体及び併用療法 |
JP7372920B2 (ja) | 2017-12-29 | 2023-11-01 | セレクティス | Car t細胞の作製を改良するための方法 |
EP3737408A1 (en) | 2018-01-08 | 2020-11-18 | Novartis AG | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US20200399383A1 (en) | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
CA3101028A1 (en) | 2018-06-05 | 2019-12-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells |
AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
CN112840031B (zh) | 2018-08-13 | 2023-03-24 | 根路径基因组学公司 | 成对的二分免疫受体多核苷酸的高通量克隆及其应用 |
TW202026006A (zh) | 2018-08-30 | 2020-07-16 | 美商Tcr2療法股份有限公司 | 使用融合蛋白進行tcr再程式化之組成物及方法 |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
WO2020069409A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
US20220047633A1 (en) | 2018-09-28 | 2022-02-17 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
AU2020241428A1 (en) | 2019-03-15 | 2021-08-12 | Cartesian Therapeutics, Inc. | Anti-BCMA chimeric antigen receptors |
KR20220004060A (ko) | 2019-04-05 | 2022-01-11 | 루트패스 제노믹스, 인크. | T-세포 수용체 유전자 어셈블리를 위한 조성물 및 방법 |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
AU2021378316A1 (en) | 2020-11-13 | 2023-06-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2024133052A1 (en) | 2022-12-19 | 2024-06-27 | Universität Basel Vizerektorat Forschung | T-cell receptor fusion protein |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68909441T2 (de) * | 1988-02-12 | 1994-02-10 | British Tech Group | Modifizierte Antikörper. |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
GB9022547D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
-
1991
- 1991-12-04 GB GB919125768A patent/GB9125768D0/en active Pending
-
1992
- 1992-12-04 WO PCT/GB1992/002252 patent/WO1993010817A1/en active IP Right Grant
- 1992-12-04 MY MYPI92002238A patent/MY111961A/en unknown
- 1992-12-04 MX MX9207032A patent/MX9207032A/es unknown
- 1992-12-04 EP EP92924783A patent/EP0616537B1/en not_active Expired - Lifetime
- 1992-12-04 KR KR1019940701885A patent/KR100271333B1/ko not_active IP Right Cessation
- 1992-12-04 ES ES92924783T patent/ES2128363T3/es not_active Expired - Lifetime
- 1992-12-04 JP JP50997393A patent/JP3383303B2/ja not_active Expired - Lifetime
- 1992-12-04 DE DE69228556T patent/DE69228556T2/de not_active Expired - Lifetime
- 1992-12-04 ZA ZA929446A patent/ZA929446B/xx unknown
- 1992-12-04 AU AU30896/92A patent/AU3089692A/en not_active Abandoned
- 1992-12-04 AT AT92924783T patent/ATE177011T1/de active
- 1992-12-04 US US08/244,316 patent/US6120766A/en not_active Expired - Lifetime
- 1992-12-04 CA CA002124964A patent/CA2124964C/en not_active Expired - Lifetime
- 1992-12-04 DK DK92924783T patent/DK0616537T3/da active
- 1992-12-04 IL IL103981A patent/IL103981A/xx not_active IP Right Cessation
-
1998
- 1998-12-07 HK HK98112902A patent/HK1011618A1/xx not_active IP Right Cessation
-
1999
- 1999-03-12 GR GR990400767T patent/GR3029683T3/el unknown
-
2004
- 2004-09-13 US US10/938,874 patent/US20050118172A1/en not_active Abandoned
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503631A (ja) * | 2006-09-13 | 2010-02-04 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
JP2014058555A (ja) * | 2006-09-13 | 2014-04-03 | Alcafleu Management Gmbh & Co Kg | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
JP2016175929A (ja) * | 2006-09-13 | 2016-10-06 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
JP2018024655A (ja) * | 2006-09-13 | 2018-02-15 | アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | カンパス−1H(Campath−1H)による多発性硬化症(MS)治療 |
Also Published As
Publication number | Publication date |
---|---|
ZA929446B (en) | 1993-08-19 |
ATE177011T1 (de) | 1999-03-15 |
DE69228556T2 (de) | 1999-07-08 |
AU3089692A (en) | 1993-06-28 |
EP0616537A1 (en) | 1994-09-28 |
US6120766A (en) | 2000-09-19 |
DE69228556D1 (de) | 1999-04-08 |
GB9125768D0 (en) | 1992-02-05 |
IL103981A (en) | 1997-07-13 |
GR3029683T3 (en) | 1999-06-30 |
CA2124964C (en) | 2005-03-15 |
HK1011618A1 (en) | 1999-07-16 |
MY111961A (en) | 2001-03-31 |
MX9207032A (es) | 1993-07-01 |
KR100271333B1 (ko) | 2000-11-01 |
WO1993010817A1 (en) | 1993-06-10 |
DK0616537T3 (da) | 1999-09-27 |
IL103981A0 (en) | 1993-05-13 |
JP3383303B2 (ja) | 2003-03-04 |
US20050118172A1 (en) | 2005-06-02 |
ES2128363T3 (es) | 1999-05-16 |
EP0616537B1 (en) | 1999-03-03 |
CA2124964A1 (en) | 1993-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07504888A (ja) | CDw52−多発性硬化症の治療のための特異抗体 | |
DE69734317T2 (de) | Anti-tnf antikörper / tnf rezeptor und methotrexat zur behandlung von autoimmunkrankheiten | |
US7629311B2 (en) | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers | |
DE60035057T2 (de) | CD40 Antagonist zur Behandlung von Psoriasis | |
US8236306B2 (en) | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers | |
RU2607022C2 (ru) | Способы и композиции для лечения волчанки | |
RU2472526C2 (ru) | Фармацевтическая композиция, содержащая анти-cd6 моноклональное антитело, пригодная для диагностики и лечения ревматоидного артрита | |
Kanwar | Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease | |
CA2473754C (en) | Treatment of ms with goat serum | |
PT1737490E (pt) | Processos de tratamento da aterosclerose | |
AU2003202093A1 (en) | Treatment of MS with goat serum | |
JP3535155B2 (ja) | 関節のT細胞介在炎症の治療のためのCDw52特異抗体 | |
DE202021004005U1 (de) | Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum | |
KR20220062025A (ko) | 요법 교체에 의한 rms의 치료 | |
WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
Marjanovic et al. | Rasmussen syndrome and long-term response to thalidomide | |
JP3973360B2 (ja) | 関節リウマチまたは皮膚疾患の処置に使用するためのcd25結合分子 | |
CN112912140A (zh) | 用于治疗化脓性汗腺炎的pan-elr+cxc趋化因子抗体 | |
WO2022075476A1 (en) | Method for treating ox40 related disease | |
CA2060384C (en) | A pharmaceutical composition containing an antibody recognizing the cdw52 antigen | |
JP2024516019A (ja) | 抗baffr抗体を使用する全身性エリテマトーデスのための治療 | |
US20240228644A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
WO2004006950A2 (de) | Verwendung von cd152, pd-1 und btla zur behandlung von autoimmunkrankheiten und entzündungen | |
US20110086046A1 (en) | Treatment of MS with goat serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071220 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081220 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091220 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101220 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101220 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111220 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111220 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121220 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term |